Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

作者：Hayashi Hidetoshi; Kurata Takayasu^*; Fujisaka Yasuhito; Kawakami Hisato; Tanaka Kaoru; Okabe Takafumi; Takeda Masayuki; Satoh Taroh; Yoshida Koji; Tsunoda Takuya; Arao Tokuzo; Nishio Kazuto; Nakagawa Kazuhiko

来源：CANCER SCIENCE, 2013, 104(1): 98-104.

DOI：10.1111/cas.12034

OTS11101 is a novel peptide vaccine that acts as an angiogenesis inhibitor by inducing cytotoxic T lymphocyte (CTL) cells that specifically target vascular endothelial cells expressing vascular endothelial growth factor (VEGF) receptor 1. We conducted a phase I study to evaluate the safety, tolerability, maximum tolerated dose, and pharmacodynamic biomarker status of this vaccine. Nine patients with advanced solid tumors received 1.0, 2.0, or 3.0 similar to mg of OTS11101 subcutaneously, once a week in a 28-day cycle. Three patients experienced grade 1 injection site reactions, which were the most frequent adverse events. Grade 2 proteinuria and hypertension each occurred in one patient. As other toxicities were generally mild, the maximum tolerated dose was not reached. Furthermore, we explored the induction of specific activated CTLs, and biomarkers related to angiogenesis. A pharmacodynamics study revealed that induction of specific CTLs was observed for a dose of 2.0 and 3.0 similar to mg. The serum concentrations of soluble VEGF receptor 1 and 2 after vaccination increased significantly compared with baseline. A microarray was performed to give a comprehensive analysis of gene expression, suggesting that OTS11101 vaccination resulted in T cell activation in a clinical setting. In conclusion, OTS11101 was well tolerated in patients up to 3.0 similar to mg once weekly and our biomarker analysis suggested that this anti-angiogenesis vaccine is biologically active. (Cancer Sci 2013; 104: 98104)

• 出版日期2013-1